Attribution of causality to AEFI, especially those considered severe, of public importance, and programmatically disruptive, are critical for ensuring vaccine safety. In 2005, WHO published an aide-mémoire to a systematic, standardized causality assessment process for serious AEFI (including clusters), providing a method for individual causality assessment to be used by staff of national ...
Serious AEFI during primary infant vaccination series in South India Extract from report of GACVS meeting of 15-16 June 2016, published in the WHO Weekly Epidemiological Record of 15 July 2016 India is currently using pentavalent (DwPT-HepB-Hib) vaccine from local manufacturers.
Since the 2013 publication of the “Causality assessment of an adverse event following immunization (AEFI), user manual for the revised WHO classification”, there has been extensive global interest in adopting the new revised causality assessment methodology for vaccine pharmacovigilance systems. WHO provided technical support and helped build capacity in countries of all WHO Regions who ...
Effective spontaneous reporting of adverse events following immunization (AEFI) is the first step to making sure that vaccine products are safe and are being safely administered.
AEFI detection primarily takes place primarily through routine passive surveillance (spontaneous reporting) which involves vaccine recipients, parents of immunized infants and children, health care workers and staff in immunization or health care facilities detecting the AEFIs and reporting them to any health care worker
To achieve this new indicator, countries need to transition from aggregated to case-based AEFI reporting. Several tools and resources have been developed and implemented to assist with this transition. Collaborations with the Uppsala Monitoring Centre (UMC), the WHO Collaborating Centre for International Drug Monitoring, resulted in the development of an online e-learning course on AEFI data ...